| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
December 31, |
|
December 31, |
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
197,670 |
|
$ |
203,887 |
|
$ |
402,325 |
|
$ |
403,836 |
Diagnostics and Genomics |
|
|
75,408 |
|
|
68,003 |
|
|
148,204 |
|
|
137,907 |
Intersegment |
|
|
(480) |
|
|
(309) |
|
|
(996) |
|
|
(507) |
Consolidated net sales |
|
$ |
272,598 |
|
$ |
271,581 |
|
$ |
549,533 |
|
$ |
541,236 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
79,586 |
|
$ |
89,336 |
|
$ |
167,947 |
|
$ |
175,278 |
Diagnostics and Genomics |
|
|
4,556 |
|
|
8,296 |
|
|
5,082 |
|
|
16,934 |
Segment operating income |
|
$ |
84,142 |
|
$ |
97,632 |
|
$ |
173,029 |
|
$ |
192,212 |
Costs recognized on sale of acquired inventory |
|
|
(183) |
|
|
(100) |
|
|
(364) |
|
|
(400) |
Amortization of intangibles |
|
|
(19,769) |
|
|
(19,125) |
|
|
(39,620) |
|
|
(38,408) |
Impact of partially-owned consolidated subsidiaries(1) |
|
|
— |
|
|
— |
|
|
— |
|
|
647 |
Acquisition related expenses and other |
|
|
525 |
|
|
8,307 |
|
|
1,114 |
|
|
8,010 |
Impairment of assets held-for-sale |
|
|
(6,038) |
|
|
— |
|
|
(6,038) |
|
|
— |
Stock based compensation, inclusive of employer taxes |
|
|
(12,958) |
|
|
(16,878) |
|
|
(24,453) |
|
|
(32,336) |
Restructuring and restructuring-related costs |
|
|
(5,518) |
|
|
(780) |
|
|
(5,607) |
|
|
(2,950) |
Corporate general, selling, and administrative expenses |
|
|
(2,197) |
|
|
(1,165) |
|
|
(4,195) |
|
|
(2,567) |
Consolidated operating income |
|
$ |
38,004 |
|
$ |
67,891 |
|
$ |
93,866 |
|
$ |
124,208 |
(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.
|